Animal experiment demonstrates that Lactococcus lactis extract reduces disease severity in mice with colitis, suggesting potential therapeutic utility for intestinal inflammation.
Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is a chronic inflammatory condition characterized by persistent intestinal inflammation. Despite advances in therapeutic strategies, effective long-term management remains challenging due to side effects and limited efficacy. Therefore, there is increasing interest in alternative approaches, including probiotics and bioactive compounds derived from microorganisms. In this study, we evaluated the effects of Lactococcus lactis KR-050L ethyl acetate extract (KR-050L-EtOAc) in a murine dextran sulfate sodium (DSS)-induced colitis model. KR-050L-EtOAc administration significantly attenuated disease severity, as demonstrated by reduced body weight loss, prevention of colon shortening, and improved histopathological features in a dose-dependent manner. In addition, KR-050L-EtOAc treatment decreased pro-inflammatory cytokine levels and preserved colonic tissue integrity. These results indicate that KR-050L-EtOAc exerts anti-inflammatory and tissue-protective effects in a DSS-induced colitis model. Given that this model reflects certain aspects of intestinal inflammation, further studies are required to determine the potential relevance of KR-050L-EtOAc in human IBD. • KR-050L-EtOAc alleviates disease severity in a murine DSS-induced colitis model. • KR-050L-EtOAc improves body weight loss and prevents colon shortening. • KR-050L-EtOAc reduces pro-inflammatory cytokine levels in DSS-induced colitis. • Lactococcus lactis KR-050L exhibits anti-inflammatory effects in an experimental colitis model.
No takes yet. Share an insight, caveat, or question.
Bak et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: